A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 87
- Registration Number
- NCT00706628
- Locations
- 🇬🇧
1239.3.4402 Boehringer Ingelheim Investigational Site, Belfast, United Kingdom
🇬🇧1239.3.4406 Boehringer Ingelheim Investigational Site, Bournemouth, United Kingdom
🇬🇧1239.3.4408 Boehringer Ingelheim Investigational Site, Brighton, United Kingdom
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 71
- Registration Number
- NCT00701766
- Locations
- 🇩🇪
1216.20.49007 Boehringer Ingelheim Investigational Site, Heidelberg, Germany
🇦🇹1216.20.43002 Boehringer Ingelheim Investigational Site, Wien, Austria
🇩🇪1216.20.49002 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
BI 811283 in Various Solid Tumours
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 124
- Registration Number
- NCT00701324
- Locations
- 🇩🇪
1247.1.49001 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau, Germany
🇩🇪1247.1.49002 Boehringer Ingelheim Investigational Site, Essen, Germany
Observational Non-Interventional Study With Spiriva Respimat in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1280
- Registration Number
- NCT00699699
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 6, Hamburg, Germany
🇩🇪Boehringer Ingelheim Investigational Site, Zirndorf, Germany
🇩🇪Boehringer Ingelheim Investigational Site 2, Wilhelmshaven, Germany
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: BI 1744 CL/tiotropium bromide fixed dose combinationDevice: Respimat® Inhaler
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 360
- Registration Number
- NCT00696020
- Locations
- 🇨🇦
1237.4.0204 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec, Canada
🇨🇦1237.4.0203 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada
🇺🇸1237.4.0104 Boehringer Ingelheim Investigational Site, Coeur d'Alene, Idaho, United States
Pramipexole ER vs. Placebo in Fibromyalgia
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 61
- Registration Number
- NCT00689052
- Locations
- 🇺🇸
248.637.01044 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸248.637.01046 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇺🇸248.637.01007 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
- Conditions
- Tourette Syndrome
- Interventions
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT00681863
- Locations
- 🇺🇸
248.642.0013 Boehringer Ingelheim Investigational Site, Orangeburg, New York, United States
🇺🇸248.642.0010 Boehringer Ingelheim Investigational Site, Providence, Rhode Island, United States
🇺🇸248.642.0029 Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2589
- Registration Number
- NCT00680186
- Locations
- 🇨🇦
1160.46.02021 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada
🇨🇦1160.46.02004 Boehringer Ingelheim Investigational Site, Saint John, New Brunswick, Canada
🇨🇦1160.46.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
Tiotropium and Salmeterol PK Study in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT00673478
- Locations
- 🇧🇪
1184.24.32001 Boehringer Ingelheim Investigational Site, Genk, Belgium
🇧🇪1184.24.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇳🇱1184.24.31001 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands
Tiotropium/Salmeterol Inhalation Powder in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Tiotropium/SalmeterolDrug: Placebo
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 207
- Registration Number
- NCT00668772
- Locations
- 🇱🇻
1184.15.37153 Boehringer Ingelheim Investigational Site, Tukums, Latvia
🇺🇸1184.15.01071 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States
🇩🇰1184.15.45054 Boehringer Ingelheim Investigational Site, Aalborg, Denmark